SCHEMBL2177740

SCHEMBL2177740

CC(C)(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4ccc(Cl)cc4)cc3)cc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SLC2A1 P11166 3/20 0.46
MCHR1 Q99705 8/20 0.44
MAPT P10636 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TMPRSS2 O15393 1/20 0.43
ABCB1 P08183 2/20 0.42
XDH P47989 1/20 0.42
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719217 0.92 KDM4E (0.48) SMN1; SMN2MCHR1MAPT
SCHEMBL2181217 0.91 TRPV1 (0.46) NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2178147 0.90 NPC1 (0.46) NPC1RAB9ASMN1; SMN2SLC2A1MCHR1
SCHEMBL2179212 0.87 TRPV1 (0.54) SMN1; SMN2MAPT
SCHEMBL2178865 0.84 TRPV1 (0.47) NPC1RAB9ASMN1; SMN2MCHR1MAPT
SCHEMBL13718608 0.83 PTPN1 (0.47) SMN1; SMN2MAPT
SCHEMBL2177022 0.81 TRPV1 (0.47) NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2178377 0.79 SDCBP (0.48) NPC1RAB9ASMN1; SMN2SLC2A1MCHR1
SCHEMBL2178384 0.79 SDCBP (0.48) NPC1RAB9ASMN1; SMN2SLC2A1MCHR1
SCHEMBL2178666 0.79 SLC2A1 (0.47) NPC1RAB9ASMN1; SMN2SLC2A1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT NPC1 158/4885RAB9A 2039/4885SMN1; SMN2 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.